HER2‐negative, node‐positive, high‐risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open‐label, phase 3 trial. Lancet Oncol. 2022;0(0):77‐90.
靶向HER2 治疗胃癌的研究进展
13. Prat A, Saura C, Pascual T, et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor‐ positive, HER2‐negative, luminal B breast cancer (CORALLEEN): an open‐label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):33‐43. 14...
modulus value were significantly different under different ER expression status, Both lymph node metastasis and Emax value were independent influencing factors, among which Emax value had the best diagnostic efficacy, which will play an important guiding role in the selection of clinical treatment plan....
Targeted Oncology: What are some of the most recent advancements in the treatment of HER2-positive breast cancer? How have they changed patient outcomes? Dempsey:The treatment of HER2-positive breast cancer has been evolving in recent years with advancements that have allowed us to better...
表3. WSG PLAN B研究常见AE 该研究证实,6周期TC方案和EC-T方案疗效相当,5年生存预后同样出色,对于具有pN0高基因组风险的HER2阴性早期乳腺癌或具有中度至高风险的pN1早期乳腺癌,6周期的TC是一种有效、安全的选择。 EBCTCG荟萃分析[5]旨在评估不同蒽环类和紫杉烷化疗方案治疗早期乳腺癌的获益与风险,其中额外分析...
The classification, he explained, would need to have a "unique biology" and be reliably defined, using a "robust assay." It would also need to have a "clinical impact," in that it should be associated with a "unique prognosis" and could be managed with a "unique treatment plan."...
HR+、HER2-早期浸润性乳腺癌中多基因检测的应用及进展 ㊀㊀ʌ摘要ɔ㊀临床上激素受体（ＨＲ）阳性乳腺癌患者治疗方案的制定通常基于病理学的各项指标㊂然而，一些临床特征相似的患者在接受相同的治疗后，疗效和预后有很大差异，这提示经典的临床病理学特点可能不足以用来制定乳腺癌综合治疗策略㊂该文研究早期...
2)HER2陽性(HER2+):一係cerbB2 score 3,一係cerbB2 score2 +FISH positive。 伸延閲讀:乳癌類型巡禮 - 與你細數HER2型乳癌的歴史 「我係HER2型呀,請講落去⋯⋯」 乳癌標靶藥Herceptin 唔知你仲記唔記得好耐之前我講過,乳癌標靶藥物一線只得一隻,就係叫Herceptin。佢要同化療一齊用先發揮出最大威力,傳...
A HER2-positive cancer diagnosis means that the cancer is likely to grow and spread more quickly and is more likely to recur. HER2-targeted treatments such as trastuzumab, pertuzumab or lapatinib may be part of the treatment plan for patients with HER2-positive cancer. If your tumor is HER2-...